CureVac NV
NASDAQ:CVAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CureVac NV
Other Long-Term Assets
CureVac NV
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CureVac NV
NASDAQ:CVAC
|
Other Long-Term Assets
€6.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Other Long-Term Assets
€20.8m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Other Long-Term Assets
€1.9m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Other Long-Term Assets
€28.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
|
Heidelberg Pharma AG
XETRA:HPHA
|
Other Long-Term Assets
€66.1k
|
CAGR 3-Years
24%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Other Long-Term Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
CureVac NV
Glance View
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.
See Also
What is CureVac NV's Other Long-Term Assets?
Other Long-Term Assets
6.6m
EUR
Based on the financial report for Dec 31, 2024, CureVac NV's Other Long-Term Assets amounts to 6.6m EUR.
What is CureVac NV's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
5%
Over the last year, the Other Long-Term Assets growth was 128%. The average annual Other Long-Term Assets growth rates for CureVac NV have been 24% over the past three years , 5% over the past five years .
